Home
overview

SMi are proud to present their 15th Annual Superbugs and Superdrugs Conference. This exciting event will bring together industry leaders from big pharma, biotechs, regulatory agencies and academia to discuss the latest in the antibacterial market. This unique conference will present attendees with a complete view into the latest in combating multi-drug resistance, diagnostics and new focus on vaccine development for the prevention of nosocomial bacterial infections.

This year’s event will also discuss the latest developments in natural product advancements and strategies to building public-private partnerships to overcome antibacterial resistance.

With senior industry representatives presenting on their own experiences and referring to case studies, success stories and failures, this event promises to be a unique forum for problem-solving debate and idea-sharing discussion.

Benefits of attending the 2013 event will include:

Understand the EMA approach to regulating antimircobials
Develop partnerships and innovative regulatory strategies
Consider novel programmes for combating antibiotic resistance
Evaluate synthesis techniques for novel inhibitors
Implement immunization strategies for C. Diff infections
Optimize modern technologies for diagnostics
Streamline high-throughput screening process for natural product-like molecules

 

 

 

This conference is a must-attend event for all those responsible for research, medical microbiology, antimicrobial therapeutics, clinical development and business development, including;

• Chief Scientific Officers
• Senior Vice Presidents
• Chief Medical Officers
• Research Scientists
• Clinical Microbiologists
• R&D Project Managers
 • Heads of Anti-Infectives Discovery
• Clinical Trials Managers
• Principal Scientists
• Senior Vice Presidents of R&D
• Business Development Managers
• Product Managers

Affinium Pharmaceuticals; Anacor Pharmaceuticals Inc; Aquapharm Biodiscovery; Aquapharm Bio-Discovery Ltd; Astellas Pharma Europe; Aurasense Therapeutics; Basilea Pharmaceutica Ltd; Biota; Boehringer Ingelheim; Cantab Biopharmaceuticals Ltd; Center For Anti-Infective Agents; Cerexa, Inc.; Creative Antibiotics; Cubist Pharmaceuticals; Da Volterra; Destiny Pharma; Euprotec; European Commision; Evolva SA; Genentech; GlaxoSmithKline; Health Protection Agency; Imperial College London; KWS Biotest; LL Silver Consulting; London School Of Economics; Meiji Seika Kaisha Ltd, Pharmaceutical Division; Merck Research Lab; Merck Research Laboratories; MorphoSys AG; MRC Human Nutrition Research; Northwestern University; Nosopharm; Novartis; Novartis Institutes for Biomedical Research Inc.; Novartis Pharma; Oxford University Clinical Research Unit; Pfizer Antibacterials RU; Pfizer Global Research and Development,; Procarta Biosystems Ltd.; Quotient Bioresearch; Quotient Bioresearch Ltd.; Rib-X Pharmaceuticals; Rinat-Pfizer; Selcia; St George's, University of London; Summit; Tiber Creek Partners; TranScrip Partners; Unilever Ltd; Unilever Ventures; University of Manchester School of Translational Medicine; Vertex Pharmaceuticals; Vivexia;

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Richard Bax

Richard Bax, Senior Partner, TranScrip Partners

9:10 The war you cannot win - but survive: how the pharma industry is mobilising to get the pipeline going

Richard Bergstrom

Richard Bergstrom, Director General, EFPIA

  • Pooling resources in public-private partnerships with the European Commision (IMI and Horizon 2020)
  • Towards reasonable and predicatble regulatory requirements
  • Bringing back old compound: what incentives are used?
  • How to preserve new antibiotics? A global compact for controlled use?
  • 9:50 Update on current R&D and the Regulatory Environment

    Richard Bax

    Richard Bax, Senior Partner, TranScrip Partners

  • Big and little pharma activity and progress
  • Report on REACT, BSAC, IDSA, Barda FP7 EU and Innovative Medicines Initiative
  • A developers view on the EMA workshop on the development of new antibacterial medicines - October 2012
  • Prospects for the future
  • 10:10 Round Table Discussion

    Richard Bax

    Richard Bax, Senior Partner, TranScrip Partners

    Richard Bergstrom

    Richard Bergstrom, Director General, EFPIA

    Ursula Theuretzbacher

    Ursula Theuretzbacher, Founder, Center For Anti-Infective Agents

    Line Matthiessen

    Line Matthiessen, Head of Infectious Diseases and Public Health Unit, European Commision

    10:45 Morning Coffee

    11:00 The use of isogenic strains in antimicrobial drug discovery

    Peter Warn

    Peter Warn, Chief Scientific Officer, Euprotec

  • Highly characterised isogenic strains
  • Uses of isogenic strains in vivo systems
  • PK/PD with isogenic strains
  • 11:40 An update on current issues and progress in C. difficile disease (CDAD)

    William Weiss

    William Weiss, Director of Pre-Clinical Services, University of North Texas Health Science Center

  • A brief history and review
  • The changing epidemiology and resistance development in CDAD
  • Transmission, Virulence factors and clinical manifestations
  • Surveillance, diagnosis and clinical testing
  • Prevention, emerging therapies and potential for efficacy
  • 12:20 Networking Lunch

    13:20 Case study: development candidate BAL30072

    Malcolm Page

    Malcolm Page, Head of Biology, Basilea Pharmaceutica Ltd

    • .Activity of BAL30072 against multi-drug resistant Gram-negative bacteria
    • .Activity of BAL30072 against Burkholderia pseudomallei and B. mallei
    • .Combined effects of BAL30072 and carbapenems in vitro
    • .Enhanced activity of BAL30072 and meropenem in animal infection models

    14:00 The design of a novel class of antibiotics for the treatment of highly resistant gram-negatives

    Erin Duffy

    Erin Duffy, Chief Scientific Officer, Rib-X Pharmaceuticals

    An exploration of the process to engineer new antibiotics for the worst bacteria
    Overcoming known resistance mechanisms
    Achieving the desired safety window 

    14:40 Armeniaspiroles : new class of antibacterials

    Cedric Couturier

    Cedric Couturier, Head of Laboratory, Sanofi

    • Gram-positive bacterial pathogens
    • Fermentation, structure isolation and characterization 
    • Total synthesis
    • Natural products

    15:20 Afternoon Tea

    15:40 Discovery of Discovery and development of Simeprevir (TMC435) and TMC647055, two novel direct antiviral agents targeting the Hepatitis C Virus

    Pierre  Raboisson

    Pierre Raboisson, Head of Medicinal Chemistry, Johnson and Johnson Pharmaceutical Research and Development

     

  • HepatitisC virus (HCV)-encoded NS3/4A protease and NS5B polymerase are essentail for viral replication and represent two attractive targets for therapeutic intervention in HCV-infected patients
  • Both NS3/4A protease and NS5B non-nucleoside inhibitors are able to decrease HCV viremia, either as monotherapy or in addition to the current standard of care therapy
  • Simeprevir (TMC435) and TMC647055 are two potent and selective inhibitors of HCV replication in genotype 1b replicon cells with EC50 values of 8 nM and 82 nM, respectively
  • Combination of these two drug candidates in an interferon-free setting is currently under investigation in the clinic
  • 16:20 GC-072: A novel resistance-breaking oxoquinolizine

    Jutta Heim

    Jutta Heim, Professor of Biotechnology chief scientific officer, Evolva SA

    • Novel oxoquinolizine
    • Broad-spectrum and potent topisomerase inhibitor
    • Different binding site than quinolones
    • Excellent in vitro coverage of Gram-positive and Gramnegative MDR pathogens
    • Favorable PK and initial Tox profile
    • Active in in vivo infection models, oral and IV

    17:00 Antibacterial Developments in Tuberculosis Research

    Anthony Coates

    Anthony Coates, Professor, St George's, University of London

  • New models are needed for antibacterial development in TB
  • Novel in vitro models which mimic TB persister bacteria
  • New murine models which are more similar to human tuberculosis than current models
  • 17:40 Chairman’s Closing Remarks and Close of Day One

    8:30 Registration & Coffee

    9:00 Chairman's Opening Remarks

    William Weiss

    William Weiss, Director of Pre-Clinical Services, University of North Texas Health Science Center

    9:10 Discovery of Bedaquiline (TMC207), a new candidate for the treatment of tuberculosis

    Jerome Guillemont

    Jerome Guillemont, Scientific Director - Fellow, Johnson & Johnson

  • Short introduction on the disease
  • A look into the current pipeline
  • History of DARQs (diarylquinoline class)/SAR
  • TMC207, properties / spectrum of activity/ in vivo efficacy/ MOA
  • 9:50 Invasive Fungal Infections: New Approaches

    Christian Felter

    Christian Felter, Associate Director, Medical Affairs, Astellas Pharma Europe

  • Review the evolving epidemiology of invasive fungal infections
  • The current treatment landscape
  • What's next?
  • 10:30 Morning Coffee

    11:00 The other superbugs: fungal pathogens and progeress in antifungal research

    Neil Ryder

    Neil Ryder, Executive Director, Infectious Diseases, Novartis Institutes for Biomedical Research Inc.

  • The burden of funal disease; old , new and emerging pathogens
  • The threat of fungal drug resistance
  • Recent advances in antifungal drugs
  • Fungi in the context of other infectious diseases
  • Trends and outlook for novel therapies
  • 11:40 Clinical Evidence for FabI Antibiotics

    Barry Hafkin

    Barry Hafkin, Chief Medical Officer, Affinium Pharmaceuticals

  • Scientific rationale for FabI inhibors, a new mechanism of action drug class
  • Clinical proof of concept in Phase 2:  safety and efficacy
  • Rationale use of a Staph specific spectrum antibiotic in clinical practice
  • 12:20 Networking Lunch

    13:20 The design and synthesis of novel antibiotic macrolones

    Adrijana Vinter

    Adrijana Vinter, Business Development Officer, Fidelta

  • SAR analysis of resistant phenotypes
  • Design of molecules to overcome resistance
  • Synthetic methodology
  • Results
  • 13:50 Partnering and working with BARDA

    Joseph Larsen

    Joseph Larsen, Chief Broad Spectrum Antimicrobials BSA Program, Biomedical Advanced Research and Development Authority

  • Background on BARDA
  • Strategic emphasis of BARDA in addressing antimicrobial resistance
  • Examples of current partnerships
  • How to engage and work effectively with BARDA
  • 14:30 New partnerships to combat antimicrobial resistance

    Line Matthiessen

    Line Matthiessen, Head of Infectious Diseases and Public Health Unit, European Commision

  • Meeting the challenges in implementing the European Commission's Action Plan on antimicrobial resistance
  • Partnerships with industry on antimicrobial resistance
  • Partnership amnog countries on antimicrobial resistance
  • The vision on futrue research under Horizon 2020
  • 15:10 Afternoon Tea

    15:40 Publicly funded antibacterial drug development in Europe

    Ursula Theuretzbacher

    Ursula Theuretzbacher, Founder, Center For Anti-Infective Agents

    • In an era of increasing antimicrobial resistance and dwindling antibiotic resources, publicly funded drug development projects intend to give much needed impulses to bridge the bottlenecks between discovery and early development and thus, for advancing promising antibacterial R&D concepts into the clinics
    • “Redevelopment” of off-patent antibiotics in academic settings funded by government grants is the only currently viable way forward
    • The urgent need for efficient and innovative concepts for developing novel as well as “redeveloping” old antibiotics demands concerted action based on private and public funding

    16:20 Novel antibiotics from marine microorganisms

    Andrew Mearns Spragg

    Andrew Mearns Spragg, Chief Technical Officer, Aquapharm Biodiscovery

  • The need for novel antibiotics and novel mechanisms of action
  • Diverse chemistry from marine mircoorganisms
  • Examples of novel antibiotics from marine sources
  • Approaches to optimize discovery of natural product chemistry
  • 17:00 Chairman’s Closing Remarks and Close of Day Three

    +

    FEATURED SPEAKERS

    Joseph Larsen

    Joseph Larsen

    Chief Broad Spectrum Antimicrobials BSA Program, Biomedical Advanced Research and Development Authority
    Jutta Heim

    Jutta Heim

    Professor of Biotechnology chief scientific officer, Evolva SA
    Line Matthiessen

    Line Matthiessen

    Head of Infectious Diseases and Public Health Unit, European Commision
    Pierre  Raboisson

    Pierre Raboisson

    Head of Medicinal Chemistry, Johnson and Johnson Pharmaceutical Research and Development
    William Weiss

    William Weiss

    Director of Pre-Clinical Services, University of North Texas Health Science Center

    Adrijana Vinter

    Business Development Officer, Fidelta
    Adrijana Vinter

    Andrew Mearns Spragg

    Chief Technical Officer, Aquapharm Biodiscovery
    Andrew Mearns Spragg

    Anthony Coates

    Professor, St George's, University of London
    Anthony Coates

    Barry Hafkin

    Chief Medical Officer, Affinium Pharmaceuticals
    Barry Hafkin

    Cedric Couturier

    Head of Laboratory, Sanofi
    Cedric Couturier

    Christian Felter

    Associate Director, Medical Affairs, Astellas Pharma Europe
    Christian Felter

    Erin Duffy

    Chief Scientific Officer, Rib-X Pharmaceuticals
    Erin Duffy

    Jerome Guillemont

    Scientific Director - Fellow, Johnson & Johnson
    Jerome Guillemont

    Joseph Larsen

    Chief Broad Spectrum Antimicrobials BSA Program, Biomedical Advanced Research and Development Authority
    Joseph Larsen

    Jutta Heim

    Professor of Biotechnology chief scientific officer, Evolva SA
    Jutta Heim

    Line Matthiessen

    Head of Infectious Diseases and Public Health Unit, European Commision
    Line Matthiessen

    Malcolm Page

    Head of Biology, Basilea Pharmaceutica Ltd
    Malcolm Page

    Neil Ryder

    Executive Director, Infectious Diseases, Novartis Institutes for Biomedical Research Inc.
    Neil Ryder

    Peter Warn

    Chief Scientific Officer, Euprotec
    Peter Warn

    Pierre Raboisson

    Head of Medicinal Chemistry, Johnson and Johnson Pharmaceutical Research and Development
    Pierre  Raboisson

    Richard Bax

    Senior Partner, TranScrip Partners
    Richard Bax

    Richard Bergstrom

    Director General, EFPIA
    Richard Bergstrom

    Ursula Theuretzbacher

    Founder, Center For Anti-Infective Agents
    Ursula Theuretzbacher

    William Weiss

    Director of Pre-Clinical Services, University of North Texas Health Science Center
    William Weiss

    Copthorne Tara Hotel

    Scarsdale Place
    Kensington
    London W8 5SR
    United Kingdom

    Copthorne Tara Hotel

    The Copthorne Tara Hotel London Kensington is an elegant contemporary four-star hotel in prestigious Kensington, located just a two minutes walk from High Street Kensington underground station, making exploring easy. The hotel offers well-appointed and comfortable guest rooms combining Standard, Superior and Club accommodation. Club rooms offer iconic views over the city and include Club Lounge access for complimentary breakfast and refreshments. Guests can sample the authentic Singaporean, Malaysian and Chinese cuisine at Bugis Street, traditional pub fare at the Brasserie Restaurant & Bar or relax with a delicious drink at West8 Cocktail Lounge & Bar.

    The Copthorne Tara Hotel boasts 745 square meters of flexible meeting space, consisting of the Shannon Suite and the Liffey Suite, ideal for hosting conferences, weddings and social events. Facilities include access to the business centre 24 hours a day, fully equipped fitness room, gift shop, theatre desk and Bureau de Change. With ample onsite parking outside the London congestion charge zone and excellent transport links via Heathrow Airport, the hotel is the perfect location for business or leisure stays. The hotel is within close proximity to the shops of High Street Kensington, Knightsbridge and Westfield London, Olympia Conference Centre, Royal Albert Hall, Kensington Palace and Hyde Park.

     

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.